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This issue of the Journal includes two articles that address a cou-
ple of important, overlooked pathologic events in liver disease –
epithelial mesenchymal transition (EMT), which is implicated in
HCV-induced carcinogenesis in the study by Akkari et al., and
sinusoidal obstruction syndrome (SOS), in which Nakamura
et al. have identiﬁed a potential new therapy in sorafenib, a drug
currently approved for the treatment of hepatocellular
carcinoma.
The study by Akkari describes a potential mechanism
whereby the NS5A protein of HCV may promote EMT, based
on cell culture and animal models. EMT is a well characterized
cellular transition in which epithelial cells acquire a phenotype
of mesenchymal cells, and in doing so lose their polarity and
cell–cell adhesions, and become motile [1,2]. The process is
critical to normal tissue development, enabling epithelial cells
to become untethered, adopt a mesenchymal phenotype, disso-
ciate from their underlying basement membrane, and migrate
to create highly specialized tissues. This so-called primary
EMT is essential to many developmental processes, including
gastrulation, neural crest formation, and heart valve develop-
ment, among others. Moreover, EMT confers immunologic priv-
ilege, allowing new tissues to form without eliciting an
inﬂammatory or immune response. Signals underlying EMT
include the soluble cytokine TGFb1 and the nuclear transcrip-
tion factors Twist, Snail, and Slug.
Those same features that are essential to EMT in development
can be hijacked to promote the development and dissemination
of cancer. Pathologic EMT in adult tissues can drive the formation
of tumor stem cells and alter the microenvironment to promote
invasion, while allowing cells to resist apoptosis or immune
attack. EMT has been implicated in a range of human tumors
including hepatocellular carcinoma (HCC), as well as breast and
colon cancers, and squamous cell cancers of the head and neck
and the urogenital system.
In this context, the study by Akkari et al. provides some evi-
dence that the NS5A protein of HCV promotes EMT in the BMEL
hepatocyte progenitor cell line, in a xenograft model, as well asJournal of Hepatology 20
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teins (but not active HCV infection). Retroviral transduction of
BMEL cells with the HCV NS5A of genotype 1b or genotype 2a
led to morphologic changes typical of EMT along with increased
motility, which was dependent upon induction of Twist2. These
effects were augmented in the presence of Ras overexpression,
which is a common feature of HCC. In vivo, livers of mice trans-
genically expressing NS5A had increased expression of mesen-
chymal genes that might also indicate EMT in vivo, although
the site(s) of expression were unclear.
The ﬁndings are provocative and support an earlier study [3]
that could explain how chronic HCV infection promotes HCC.
Moreover, a subset of HCCs can have a stem cell-like signature,
which may reﬂect those in which the EMT program is driving
the tumor’s formation [4–7] – typically, these tumors have a
poorer prognosis.
Despite this emerging association between EMT, stem cells,
and HCC, the evidence is not ironclad for a role of NS5A in
EMT associated with this neoplasm. First, none of the models
in this study support HCV replication and therefore the levels
of NS5A and their cellular context may not be physiologically
relevant. Second, there are no studies identifying features of
EMT in livers from patients with HCV, or evidence that EMT
correlates with cancer risk or behavior in this cancer. Third,
the full program of EMT is not convincingly demonstrated in
the Akkari study. Finally, it is not clear how EMT associated
with NS5A expression would explain the almost universal
requirement for advanced ﬁbrosis or cirrhosis to be present
before HCC arises. Does EMT only occur in advanced disease?
Is EMT necessary, but not sufﬁcient for HCC, or does it occur
in only a subset of tumors? These and other questions await
further study.
One contribution of EMT to liver disease that is not likely is
its potential role in ﬁbrogenesis. A number of earlier studies
implicated EMT in hepatic ﬁbrosis, suggesting it leads to the
generation of ﬁbrogenic cells from hepatocytes [8,9], and while
it appears that EMT fosters ﬁbrogenesis in some way [10], it is
unlikely to do so by simply generating more matrix-producing
cells from epithelium. In fact, several recent studies fail to
show true EMT in liver [11–13], and there is a growing appre-
ciation that EMT can readily occur in culture, but this does not
reﬂect its capacity to occur in vivo [14].
Sinusoidal obstruction syndrome (SOS), previously called
veno-occlusive disease, is a catastrophic illness in which severe12 vol. 57 j 935–936
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injury to the sinusoidal endothelial cells in the pericentral region
leads to sinusoidal ﬁbrosis, necrosis of pericentral hepatocytes,
and narrowing, then ﬁbrosis of central veins [15]. The syndrome
typically occurs in response to chemotherapeutic alkylating
agents (e.g., oxaliplatin) used for metastatic colon or breast can-
cer, and presents clinically with rapid onset of abdominal pain,
ascites, and jaundice, owing to the sudden obstruction to outﬂow
of blood from the hepatic parenchyma. Drs. George McDonald
and Laurie DeLeve have been among the leaders in characterizing
the clinical and cellular features of this illness, respectively, and
in 1999 Dr. DeLeve described a new animal model of SOS due
to administration of the toxin monocrotaline [16], which leads
to speciﬁc injury to sinusoidal endothelial cells, liberating the
enzyme matrix metalloproteinase-9 as well as leading to loss of
the vasodilator nitric oxide [17].
In the study by Nakamura et al. in this issue of the Journal,
the authors reasoned that because SOS is also associated with
elevated circulating levels of the angiogenic cytokine VEGF,
then antagonizing its signaling with the approved drug sorafe-
nib, might improve the syndrome. Indeed, rats pretreated with
standard doses of sorafenib either 12 and 36 h before monocro-
taline administration had marked attenuation of SOS features,
associated with reduced injury and improved survival after
partial hepatectomy. In addition, expression and activity of
MMP-9 and the intracellular kinase c-jun N-terminal kinase
(JNK) were both reduced by sorafenib.
While these results are largely descriptive, they are hopeful
nonetheless, ﬁrst by drawing much-needed attention to this
neglected syndrome and second, by providing a practical
approach that might merit studies in humans, since sorafenib
is already approved for use in HCC. However, in this rodent
study the drug was administered prophylactically, and
although this might be possible for patients at risk for SOS,
sorafenib is not without some adverse symptoms that might
be difﬁcult for patients undergoing metastatic colorectal or
breast cancer treatment. Moreover, the apparent salutary effect
on MMP-9 and JNK does not deﬁnitely link these mediators to
the cause of attenuated disease. Additionally, the cellular and
molecular target(s) of sorafenib and the sources of MMP-9
and JNK are not clear, and could derive from a number of res-
ident cell types besides sinusoidal endothelial cells, in particu-
lar hepatic stellate cells.
Despite these limitations, efforts like this study to repurpose
approved drugs for new indications such as SOS are part of an
accelerating trend in biomedicine, and have been the recent focus
of an effort in the U.S. by the National Center for Advancing
Translational Sciences (www.ncats.nih.gov/research/reengineer-
ing/rescue-repurpose/therapeutic-uses/therapeutic-uses.html).
In the case of SOS, this effort to ﬁnd new treatments cannot come
a moment too soon.936 Journal of Hepatology 201Conﬂict of interst
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